Time for diabetologists to measure their hormone: utility and interpretation of C peptide in Type 1 diabetes

> Professor Andrew Hattersley email: A.T.Hattersley@exeter.ac.uk www.diabetesgenes.org



#### Is Diabetes really Endocrinology?

Ende	ocrinology	Diabetes
Diagnosis	+++	_
Treatment	+	+++
Patient centered	?	+++
MDT	+	+++
Science based	+++	+
Trial based	+	+++
Needs clever Drs!	+++	?
Measure hormone	+++	-
Diagnostic tests	+++	-

What does a consultant physician offer in diabetes above a specialist nurse or GP?

Following NICE guidance ×

Unique treatment or investigation ×

Treatment expertise ?

Diagnostic expertise  $\checkmark$ ?

Interpretation of investigations  $\checkmark$ ?

How good are your diabetes diagnostic/ investigation skills?

# 2 cases of ? Cushing's Endocrine v Diabetes




Presentation- Hypertension Investigations- Endocrinology 24hr Urinary cortisol x3 Dex suppression test 9am cortisol/ ACTH Pituitary MRI Adrenal CT IPPS MRI Chest, Abdo, Pelvis Ostreoscan





Investigations- Diabetes Fasting insulin /C peptide Fasting TG/HDL Adiponectin/Leptin Genetic tests: LaminAC, PPARG

Presentation- Diabetes Investigations- Diabetes 24hr Urinary cortisol x 1 ICA/GAD negative C peptide can be used to measure endogenous insulin secretion in patients on insulin.



C-peptide cleaved from proinsulin during insulin production Equi-molar with insulin

C-peptide measures endogenous insulin secretion

Why do Insulin Endocrinologists not measure their hormone?

#### Difficult to measure

Unstable Need to stop insulin and perform a MMTT

#### Don't need to measure

Can use clinical features and antibodies Won't alter treatment

#### Making C-peptide measurement easier




Tim McDonald

#### Urinary C peptide Creatinine Ratio

- 10% C peptide excreted in Urine
- Urine measures practical and easy
- Stable at room temp for 72 hours in boric acid
- Using creatinine ratio accounts for dilution.
   Spot sample represents insulin secretion since last micturition
- Can be posted NHS cost £11 through biochemistry ar Royal Devon and Exeter hospital, Exeter




# A home postprandial UCPCR is a non-invasive alternative in routine practice



# UCPCR < 0.2nmol/mol is sensitive & specific equivalent of serum C pep <0.2 nmol/l


0.2 nmol/l



Besser et al Diabetes Care 2011

# We can now measure C peptide easily

#### Blood C peptide *is* stable at room temperature



Plasma C peptide -can be measured easily in all hospitals

Chemiluminescence assay

Sensitive and robust


Measurable on standard biochemistry platforms

## We can now measure C peptide easily

Do not need to stimulate endogenous insulin secretion as fasting well correlated with stimulated Besser et al Diab Med 2012


Stopping fast acting insulin not needed Besser et al Diab Med 2012

Non fasting random with glucose works well



Berger et al Scan J Clin Invest 2000

# Non-fasting random blood C-peptide is both sensitive & specific



Random C peptide (rCP) and values taken during MMTT

Take >60min post meal Avoid hypoglycaemia (<4mmol/l) r=0.913, p<0.0001

Highly predictive of insulin deficiency (<200pmol/l)

Hope, Jones Diabetes Medicine 2016

Using C-peptide to diagnose subtypes of diabetes

#### **Obese young diabetes**



#### Mr 33

33 yr UK Caucasian Factory Worker
Thirsty drinking Coca Cola
Slightly dehydrated
BMI 33 kg/m<sup>2</sup>
Glucose 33 mmol/l
Ketones +

5 years later HbA1c 8.2%

**Diagnosis? Treatment?** 



# Mr 33 Uno

33 yr UK Caucasian Factory Worker
Thirsty drinking Coca Cola
Slightly dehydrated
BMI 33 kg/m<sup>2</sup>
Glucose 33 mmol/l
Ketones +

Treated with 33U Mixtard bd

4 years later HbA1c 8.2%

Diagnosis T1D Treatment: Basal bolus Insulin ?Metformin ?Insulin pump DAFNE



# Mr 33 Duo

33 yr UK Caucasian Factory Worker Thirsty drinking Coca Cola Slightly dehydrated BMI 33 kg/m<sup>2</sup> Glucose 33 mmol/l Ketones +

Treated with 33U Mixtard bd

5 years later HbA1c 8.2%


**Diagnosis** T2D

Treatment: Diet Metformin

? GLP1 agonists? Intermediate insulin

Type 2 education

# Diagnosing T1D in slim elderly patients patients diag T1D > 35yr 56% misclassified



Hope et al 2015, BJGP n=601

n

### T1D – why do we get it wrong in adults? Usually use Clinical Criteria +/- autoantibodies

#### **Clinical Criteria**

Broad imprecise guidance only (ADA,EASD,WHO) T1D: diagnosed "young", "slim", "DKA presentation" No cut offs define against future absolute insulin deficiency


#### Evidence base – weak

Systematic review: Only 10 studies clinical features v C peptide outcome Favoured age of diagnosis (<35yr) over BMI (Shields et al BMJ Open 2015)

#### **Autoantibodies**

Assays not standardised > 50% UK labs measure rodent ICA! Prospective studies almost entirely children Not routinely measured in adults

## Recognising Type 1 diabetes in elderly population Why GAD antibodies are not ideal



#### Patients tested alters interpretation


< 20 years – 95% T1D Positive predictive value 99.6% Specific test – false positives rare (0.4%)

#### > 40 years - 5% T1D

Positive predictive value 60% Non specific – false positives common (40%)

If you diagnose "T1D" in adults using GAD - 40% will have T2D Therefore LADA will be a mixture of Type 1 and Type 2

### UCP/Cr ratio allows differentiation of Type 1 from Type 2 if over 5 years duration



# Mr 33



33 yr UK Caucasian Factory Worker
Thirsty drinking Coca Cola
Slightly dehydrated
BMI 33 kg/m<sup>2</sup>
Glucose 33 mmol/l
Ketones +

Treated with 33U Mixtard bd

4 years later HbA1c 8.2%

Diagnosis? Treatment?

UCPCR 0.17 nmol/mmol Type 1

# Mr 33



33 yr UK Caucasian Factory Worker
Thirsty drinking Coca Cola
Slightly dehydrated
BMI 33 kg/m<sup>2</sup>
Glucose 33 mmol/l
Ketones +

Treated with 33U Mixtard bd

4 years later HbA1c 8.2%

Diagnosis? Treatment?

UCPCR 1.7 nmol/mmol Type 2

# Dorothy



Age diagnosis	51 yr
Present Age	69yr
BMI	27
Initial Treatment	OHA for 4 years then insulin
Present Treatment	Metformin 1g bd Insulatard 22/-/16/-
Clinical Problem	Variability in glucose – severe problem with hypos HbA1c 8.9%

UCPCR 0.1 nmol/mmol

#### Type 2 patients can become C peptide negative



Suzy Hope

174 insulin-treated subjects T2D on clinical criteria

diagnosed <u>></u>45 years (median 58yrs IQR 50-65)
started insulin >12 m (median 72 m, IQR 36-123) post-diagnosis

Tested with UCPCR and then MMTT 5 (3%) C Peptide negative (stimulated <200pmol) 2/5 Antibody (GAD positive)


Major problems: hypos and inappropriate treatment

Need Type 1 education and treatment

Oakes, Shepherd, Hattersley et al Diabetic Medicine 2013

# Endogenous insulin secretion, not clinical diagnosis determines risk of hypoglycaemia

- Comparison of CGM assessed hypoglycaemia in 17 matched pairs
- Insulin treated Type 2 diabetes, onset age >35, >2 years to insulin
- Low/high C-peptide groups not distinguishable by clinical characteristics



S Hope & A Jones

#### Peter

# His family




15 yr diagnosed 14 yr glucose 19 mmol/l Treated basal bolus insulin 0.5U/kg HbA1c 8.2%



"Type 1 and Type 2" UCPCR 1.3 nmol/mmol

Father insulin for 18 years UCPCR 0.7 nmol/mmol Autosomal dominant, non insulin dependent

#### UCP/Cr ratio allows differentiation of Type 1 from MODY >5yrs post diagnosis



#### Large impact on treatment

HNF-1A MODY diagnosed on molecular genetic testing



Stopped insulin Started a single half tablet of gliclazide Control improved HbA1c 8.2% to 6.5% All "Type 1" stopped insulin and went on sulphonylurea tablets with better control.

All "Type 2" stopped treatment and went on sulphonylurea tablets with better control.


Shepherd Diab Med 2009

# Clare



Age diagnosis	20
Present Age	22
BMI	25
Initial Glucose and Treatment	Glucose 21 Basal bolus insulin
Present Treatment	Novorapid 4/4/4/- Glargine -/-/-/20
Clinical Problem	HbA1c 6.9% No hypos Occasional monitoring

## C peptide continues well after diagnosis in Type 1 diabetes



Oram McDonald Hattersley UNITED study unpublished

Can UCPCR aid management of paediatric patients with Type 1 diabetes?

UCPCR positive Type 1 (AB+) patients: older at diagnosis and had a shorter duration

	UCPCR <0.2nmol/mmol 'negative' n=549 Median (IQR)	UCPCR ≥0.2nmol/mmol 'positive' n=185 Median (IQR)	p value
Age at Diagnosis (Years)	6 (3 <i>,</i> 9)	11 (8,13)	<0.0001
Duration (Months)	74 (44,112)	15 (4,31)	<0.0001

# UCPCR positive Type 1 (AB+) patients were on less insulin but had same level of HbA1c

	UCPCR	UCPCR	
	<0.2nmol/mmol	≥0.2nmol/mmol	
	'negative'	'positive'	P value
	n=549	n=185	
	Median (IQR)	Median (IQR)	
Insulin Dose	0.93 (0.76, 1.14)	0.68 (0.5, 0.97)	<0.0001
(u/kg/day)	0.95 (0.70, 1.14)	0.08 (0.5, 0.97)	<0.0001
HbA1c		70 (61 94)	0.75
(mmol/mol)	70.5 (62 <i>,</i> 81)	70 (61, 84)	0.75

UCPCR positive patients could increase insulin to achieve better control

More aggressive treatment protective against complications and beneficial when UCPCR reduces over time

#### When it helps to measure C-peptide in Type 1?

- 1. To assess if patient on insulin is making their own insulin
  - Assessment of T1D honeymoon
  - Diagnosis –type 1 vType 2/MODY
  - Guidance on other therapy
- 2. To assess if type 2 with variable glucose values who has gone on insulin is still producing own insulin
- 3. To detect/confirm severe insulin resistance
- 4. ? Stratify for treatment response to third line agents in T2D

# Interpretation of measurement of C-Peptide is needed

Need to interpret results carefully Glycaemia alters interpretation

UCPCR overlap between T1D and non diabetic controls

**Needs Experts** 

If we measure our hormone Diabetes is Endocrinology!

	Endocrinology	Diabetes
Diagnosis	+++	+++
Treatment	+	+++
Patient centered	?	+++
MDT	?	+++
Science based	+++	++
Trial based	+	+++
Needs clever Drs	! +++	+++
Measure hormon	e +++	++